Advertisement

Topics

FDA Approves Imbruvica as First and Only Approved Therapy for Patients with Chronic Graft-Versus-Host-Disease

15:54 EDT 3 Aug 2017 | Speciality Pharma Journal

HORSHAM, Pa., Aug. 2, 2017 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of adult patients with chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy.1 IMBRUVICA is the first and only FDA-approved medication for adult patients with cGVHD, a potential consequence of …

Original Article: FDA Approves Imbruvica as First and Only Approved Therapy for Patients with Chronic Graft-Versus-Host-Disease

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Imbruvica as First and Only Approved Therapy for Patients with Chronic Graft-Versus-Host-Disease"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...